eribulin mesylate + erlotinib + eribulin mesylate + erlotinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Feb 22, 2010 → Jan 18, 2017
NCT ID
NCT01104155About eribulin mesylate + erlotinib + eribulin mesylate + erlotinib
eribulin mesylate + erlotinib + eribulin mesylate + erlotinib is a phase 2 stage product being developed by Eisai for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01104155. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01104155 | Phase 2 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer